Remedy Biologics

Executive Summary

Remedy Biologics (RemedyBio) is a Dublin-based nano-scale biotechnology company founded in 2018, dedicated to deciphering immune biology to develop novel small molecule therapies. The company's proprietary ultra-high throughput discovery platform maps cellular function directly from patient-derived samples, enabling the identification of therapeutic targets and candidates that harness the human immune system. By focusing on challenging diseases mediated by immune dysfunction, RemedyBio aims to unlock new treatment paradigms in inflammation, autoimmunity, and oncology. The platform's ability to screen vast chemical libraries at the nano-scale positions it to efficiently generate lead compounds with high specificity and reduced toxicity. As a private, early-stage entity with no disclosed funding rounds or pipeline specifics, RemedyBio operates with limited public visibility. However, its technology addresses a critical bottleneck in drug discovery—directly translating human biology into therapeutic hits. The company's location in Ireland's growing biotech hub and its niche in small molecule immunology suggest potential for strategic collaborations. Upcoming catalysts, including a Series B financing and the advancement of a lead program toward IND, will be pivotal in validating the platform and driving valuation. The conviction score reflects the firm's innovative approach balanced against the high-risk, early-stage nature of the venture.

Upcoming Catalysts (preview)

• Q4 2026Series B Financing70% success
• Q1 2027Lead Program IND Submission40% success
• Q3 2026Pharma Partnership or Licensing Deal30% success